Bordeaux, France – March 3, 2022 – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER^®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the grant by the USPTO (United States Patent and Trademark Office) in the United States, of their new patent US 11 097093.

The patent named “Method for managing a heart pump” covers various therapeutic modes of the ICOMS FLOWMAKER^® , the world’s first and only fully implantable electro-physiological cardiac assistance device for the treatment of severe heart failure.

Besides being totally adaptable, the mini intracardiac pump developed by FineHeart is the only circulatory assistance device capable of synchronizing with the opening of the aortic valve to increase the native cardiac
function with every heartbeat. The algorithms used in the ICOMS FLOWMAKER^® represent the real intelligence of the device. Much like the algorithms used in pacemakers, they allow to recognize the patient’s effort, identify arrhythmias and to adjust the level of assistance provided in real time.

This key patent adds to FineHeart’s strong international portfolio of more than 72 patents in 18 various fields of expertise spanning from the design, the control, to the surgical implantation of the ICOMS FLOWMAKER^®.